

PROVIDER QUICK POINTS

PROVIDER INFORMATION



June 8, 2022

Medical Drug Management Update – Alpha-1 Proteinase Inhibitors

As stewards of healthcare expenditures for our subscribers, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) is charged with ensuring they receive the highest quality, evidence-based care. This is accomplished through development medical policies and management of the policies to include the PA process. The primary purpose of the PA process is to ensure that evidence-based care is provided to our subscribers, driving quality, safety, and affordability

Effective July 4, 2022, Blue Cross will be updating medical policy II-206 for Alpha-1 Proteinase Inhibitor prior authorization requirement review criteria to remove a step therapy requirement to try ProLactin-C prior to Aralast, Glassia, or Zemaira. With the policy update, the Commercial Preferred Medical Drug Program List will be updated accordingly.

Policy #	Medical Policy Being Updated	New Policy	Prior Authorization Requirement	Line(s) of Business
II-206	• Alpha-1 Proteinase Inhibitor	No	Existing	Commercial

Products Impacted

This information update applies to commercial lines of business.

Reminder Regarding Medical Policy Updates & Changes:

Medical Policy changes are communicated in the “Upcoming Medical Policy Notifications” section of the Blue Cross Medical and Behavioral Health Policy website. The Upcoming Policies section lists new, revised, or inactivated policies approved by the Blue Cross Medical and Behavioral Health Policy Committee and are effective at minimum 45 days from the date they were posted. To access the website:

- Go to bluecrossmn.com/providers website
- Under Medical management, select [Medical and Behavioral Health Policies](#) webpage
 - Select “See Upcoming medical and behavioral health policy notifications” to view the policy criteria changes
 - Select “Preferred Medical Drug Program – Commercial plans (PDF)” to view the Preferred Medical Drug Program list.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.